Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 1, 2009, Pages 17-21

  Kerola, Markku ^a   Vuolteenaho, Katriina ^a   Kosonen, Outi ^a   Kankaanranta, Hannu ^a   Sarna, Seppo ^b   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTOXIN; IBUPROFEN; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE A2; THROMBOXANE B2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SINGLE DRUG DOSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BUTANONES; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IBUPROFEN; MALE; SULFONAMIDES; THROMBOXANE B2;

EID: 58149085807     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00332.x     Document Type: Article

References (40)

1. Vane J. Towards a better aspirin. Nature 1994 367 : 215 6.
2. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004 329 : 948.
3. Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005 1 CD005115.
4. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005 7 : R644 65.
5. Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005 21 : 715 22.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 343 : 1520 8.
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 102.
8. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006 99 : 132 40.
9. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 332 : 1302 8.
10. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997 18 : 30 4.
11. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998 104 : 413 21.
12. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998 104 : 2S 8S.
13. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999 96 : 7563 8.
14. Kankaanranta H, Moilanen E, Vapaatalo H. Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions. Inflammation 1993 17 : 417 25.
15. Panara MR, Padovano R, Sciulli MG, Santini G, Renda G, Rotondo MT et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin Pharmacol Ther 1998 63 : 672 81.
16. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999 50 : 661 7.
17. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999 290 : 276 80.
18. Moilanen E, Alanko J, Seppälä E, Vapaatalo H. Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Agents Actions 1988 24 : 387 94.
19. Stichtenoth DO, Frölich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003 63 : 33 45.
20. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007 82 : 85 94.
21. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994 271 : 1705 12.
22. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000 43 : 4 13.
23. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology (Oxford) 1999 38 (Suppl 1 33 8.
24. Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001 48 : 339 46.
25. Rainsford KD, Members of the Consensus Report Group on Nimesulide. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006 22 : 1161 70.
26. Rainsford KD. Current status of the therapeutic uses and actions of the preferential cyclooxygenase-2 NSAID, nimesulide. Inflammopharmacology 2006 14 : 120 37.
27. http://www.emea.europa.eu/pdfs/human/referral/nimesulide/172404en.pdf/ July 2008.
28. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors. Inflamm Res 1995 44 : 253 7.
29. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997 46 : 437 46.
30. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 296 : 558 66.
31. Marbet GA, Yasikoff Strub ML, Macciocchi A, Tsakiris DA. The effect of nimesulide versus placebo on hemostasis in healthy volunteers. Eur J Clin Pharmacol 1998 54 : 383 7.
32. Cullen L, Kelly L, Connor SO, Fitzgerald DJ. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 1998 287 : 578 82.
33. Hawkey CJ. COX-2 inhibitors. Lancet 1999 353 : 307 14.
34. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993 90 : 11693 7.
35. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975 72 : 3073 6.
36. Bunting S, Moncada S, Vane JR. The prostacyclin - thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983 39 : 271 6.
37. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclooxygenases. Biochem J 1999 339 : 607 14.
38. Davies NM. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclooxygenase-2 inhibition? Clin Pharmacokinet 1997 33 : 404 16.
39. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 2004 64 : 2315 43.
40. Huang JQ, Sridhar S, Hunt RH. Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 1999 107 : 55S 61S.